journal article·2024-08-19Open access

Surgery Combined with Local Implantation of Doxorubicin-Functionalized Hydroxyapatite Halts Tumor Growth and Prevents Bone Destruction in an Aggressive Osteosarcoma

Yang Liu, Tova Corbascio, Jintian Huang, Jacob Engellau, Lars Lidgren, Magnus Tägil, Deepak Bushan Raina

Abstract

Osteosarcoma treatment comprises pre-surgical chemotherapy followed by radical surgery and further chemotherapy cycles, but the prognosis has been far from satisfactory. No new drugs or treatment modalities have been developed for clinical use in the last four decades. We describe a nano-hydroxyapatite (HA)-based local drug delivery platform for the delivery of doxorubicin (DOX), a cornerstone drug in osteosarcoma treatment. The efficacy of the developed drug delivery system was evaluated in an orthotopic human osteosarcoma xenograft in the proximal tibia of mice. After tumor development, the tumor was surgically resected and the void filled with the following: (1) No treatment (G1); (2) nHA only (G2); (3) DOX-loaded nHA (G3). In-vivo tumor response was assessed by evaluating the tumor-induced osteolysis at 2 weeks using micro-CT followed by in-vivo PET-CT at 3 weeks and ex-vivo micro-CT and histology. Micro-CT imaging revealed complete destruction of the tibial metaphysis in groups G1 and G2, while the metaphysis was protected from osteolysis in G3. PET-CT imaging using 18F-FDG revealed high metabolic activity in the tumors in G1 and G2, which was significantly reduced in G3. Using histology, we were able to verify that local DOX delivery reduced the bone destruction and the tumor burden compared with G1 and G2. No off-target toxicity in the vital organs could be observed in any of the treatment groups histologically. This study describes a novel local drug adjuvant delivery approach that could potentially improve the prognosis for patients responding poorly to the current osteosarcoma treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Sarcoma Diagnosis and Treatment · Bone Tumor Diagnosis and Treatments · Orthopedic Infections and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, 221 00 Lund, Sweden

Funding

Swedish Research Council · Royal Physiographic Society of Lund

References (32)

Show source-provided references
1. Clinical cancer research: The past, present and the future10.1038/nrclinonc.2014.153 ↗
2. New Horizons in the Treatment of Osteosarcoma10.1056/NEJMra2103423 ↗
3. Cancer prevention: From 1727 to milestones of the past 100 years10.1158/0008-5472.CAN-09-1750 ↗
4. Responsive nanomedicines enhanced by or enhancing physical modalities to treat solid cancer tumors: Preclinical and clinical evidence of safety and efficacy10.1016/j.addr.2021.114075 ↗
5. Surgical resection of relapse may improve postrelapse survival of patients with localized osteosarcoma10.1007/s11999-012-2590-2 ↗
6. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival10.1002/1097-0142(19950301)75:5<1084::AID-CNCR2820750506>3.0.CO;2-F ↗
7. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols10.1200/JCO.2002.20.3.776 ↗
8. Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma10.1007/978-3-319-04843-7_1 ↗
9. Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation10.1097/MD.0000000000015582 ↗
10. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success10.1200/JCO.2014.59.4895 ↗
11. Survival and prognosis with osteosarcoma: Outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort10.1016/j.ejca.2018.11.027 ↗
12. Targeted drug delivery to tumors: Myths, reality and possibility10.1016/j.jconrel.2011.06.001 ↗
13. Controlled release for local delivery of drugs: Barriers and models10.1016/j.jconrel.2014.04.048 ↗
14. Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma10.1186/s13046-023-02731-z ↗
15. Advances in Osteosarcoma10.1007/s11914-023-00803-9 ↗
16. Drug delivery: The heart of the matter10.1038/nmat2309 ↗
17. Sustained and controlled delivery of doxorubicin from an in-situ setting biphasic hydroxyapatite carrier for local treatment of a highly proliferative human osteosarcoma10.1016/j.actbio.2021.07.016 ↗
18. Liu, Y., Nadeem, A., Sebastian, S., Olsson, M.A., Wai, S.N., Styring, E., Engellau, J., Isaksson, H., Tägil, M., and Lidgren, L. (2022). Bone mineral: A trojan horse for bone cancers. Efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin. Mater. Today Bio, 14.10.1016/j.mtbio.2022.100227 ↗
19. Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes10.1038/bjc.2013.549 ↗
20. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas10.1073/pnas.0607705103 ↗
21. Targeted Drug Delivery: Trends and Perspectives10.2174/1567201818666210609161301 ↗
22. Delivering precision oncology to patients with cancer10.1038/s41591-022-01717-2 ↗
23. Pilavaki, P., Gahanbani Ardakani, A., Gikas, P., and Constantinidou, A. (2023). Osteosarcoma: Current Concepts and Evolutions in Management Principles. J. Clin. Med., 12.10.3390/jcm12082785 ↗
24. Hum, N.R., Martin, K.A., Malfatti, M.A., Haack, K., Buchholz, B.A., and Loots, G.G. (2018). Tracking Tumor Colonization in Xenograft Mouse Models Using Accelerator Mass Spectrometry. Sci. Rep., 8.10.1038/s41598-018-33368-0 ↗
25. Liu, Z., Wang, Y., Kabraji, S., Xie, S., Pan, P., Liu, Z., Ni, J., and Zhao, J.J. (2019). Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method. Sci. Rep., 9.10.1038/s41598-018-36874-3 ↗
26. Liu, G., Yang, L., Chen, G., Xu, F., Yang, F., Yu, H., Li, L., Dong, X., Han, J., and Cao, C. (2021). A Review on Drug Delivery System for Tumor Therapy. Front. Pharmacol., 12.10.3389/fphar.2021.735446 ↗
27. Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo10.1016/j.amjsurg.2011.06.027 ↗
28. Strategies for large bone defect reconstruction after trauma, infections or tumour excision: A comprehensive review of the literature10.1186/s40001-021-00593-9 ↗
29. Bone regeneration strategies: Engineered scaffolds, bioactive molecules and stem cells current stage and future perspectives10.1016/j.biomaterials.2018.07.017 ↗
30. Doxorubicin: The good, the bad and the ugly effect10.2174/092986709788803312 ↗
31. The ancillary effects of nanoparticles and their implications for nanomedicine10.1038/s41565-021-01017-9 ↗
32. Liu, Y., Sebastian, S., Huang, J., Corbascio, T., Engellau, J., Lidgren, L., Tägil, M., and Raina, D.B. (2022). Longitudinal in vivo biodistribution of nano and micro sized hydroxyapatite particles implanted in a bone defect. Front. Bioeng. Biotechnol., 10.10.3389/fbioe.2022.1076320 ↗